|6 December 2016|
Scotland
One of the world’s leading clinical informatics companies has opened an office at the largest acute hospital in Western Europe.
Aridhia’s software is being used to advance the development of bespoke treatments for patients with diseases including cancer, MS and arthritis. Its new office in the University of Glasgow’s Clinical Innovation Zone in the hospital’s Teaching and Learning Centre – alongside the Stratified Medicine Scotland Innovation Centre (SMS-IC) – places them at the heart of Scotland’s national hub for precision medicine.
The team will focus on data and analytics innovation in biomedical research and precision medicine.
Since 2014, Aridhia has worked closely with the SMS-IC, which uses AnalytiXagility as its informatics platform to collect, manage and analyse the vast volumes and diversity of data needed to realise the potential of stratified medicine.
This move places Aridhia at the heart of precision medicine activity in Scotland and enables closer collaborative working between the company, University and SMS-IC, with a focus on the development of data-driven, operational clinical services that will benefit patients within Scotland and further afield.
Chris Roche, CEO at Aridhia commented: “We are excited by the innovative and important work produced by the University and SMS-IC, and are pleased we are able to make our own valuable contribution in this field.
“Our new office puts us at the forefront of the precision medicine frontier, and it’s fulfilling to work alongside our peers in Scotland’s national hub for precision medicine, and collaborate so closely on life-changing projects.
“The work happening here in Glasgow, including projects focused on pancreatic cancer, COPD, multiple sclerosis and rheumatoid arthritis, will benefit millions of people around the world, finding better treatments for an array of medical conditions that are targeted to the individual’s needs, faster than ever before.
“We are delighted that our software platform service has made such a significant contribution to this work, and we look forward to continuing to assist these vital research projects, and others around the world, for many years to come.”
